The single most valuable regulatory asset in the U.S. generic pharmaceutical industry is not a patent. It is the absence […]

Part I: The Architecture of Pharmaceutical Value — Patents as Financial Instruments What a Drug Patent Actually Is (And What

The $236 billion Loss of Exclusivity wave hitting between 2025 and 2030 is the most concentrated revenue erosion event in

Intellectual property has long been treated as a defensive asset — a legal shield erected around a discovery to keep

Introduction: The Paragraph IV Filing as Corporate Weapon A Paragraph IV certification is the most powerful offensive instrument in the

1. The Core Tension: Why Launch Pricing Breaks Finance Departments Pharmaceutical launch pricing is the only commercial decision in modern

The generic drug industry runs on a paradox. Generics fill more than 90% of all U.S. prescriptions yet account for

Branded drugs generating $356 billion in worldwide sales face patent expiration between 2023 and 2028. Every one of those assets

1. Market Scale and Growth Trajectory Sizing the Opportunity The global generic drug market sat between $488 billion and $491